Acknowledgement
The authors are thankful to Lalit Saxena and Gajanan Joshi of Millipore India Pvt. Ltd. for technical assistance during the
study.
RAKESH KUMAR, PhD, is a director and S.V. KAPRE, PhD, is an executive director of the Serum Institute of India, Ltd., Pune, India, PRIYABRATA PATTNAIK, PhD, is a technical manager of the biomanufacturing sciences network at Millipore Singapore Pte. Ltd., Singapore, +65.6403.5308,
priyabrata_pattnaik@millipore.com
SUBHASIS BANERJEE, PhD, is a manager of process applications and M.S. MAHADEVAN is a vice president of the bioprocess division at Millipore India Pvt. Ltd., Bangalore, India.
References
1. Cherry JD, Heininger U. Pertussis and other Bordetella infections, In: Feigin RD, Cherry JD, eds. Textbook of Pediatric
Infectious Diseases, 4th edn. WB Saunders; Philadelphia, PA. 1998:1423–40.
2. Conly JM, Johnston BL. The role of the acellular pertussis vaccine and the demise of the 'Pertussis Pete'. Can J Infect
Dis. 2001:98:15–17.
3. Pertussis Vaccination : Use of Acellular Pertussis vaccines among infants and young children, Recommendations of the advisory
committee on immunization practices (ACIP); Morbidity and mortality weekly report, US Department of Health and Human Services.
1997;22: Mar 28.
4. Corbel MJ, Corbel MJ, Toxicity and potency evaluation of pertussis vaccine. Vaccines. 2004:89–100.
5. Sundaran B, Palianiappan C, Rao YUB, Boopathy R, Bhau RLN. Tangential flow filtration technology applicable to large scale
recovery of diptheria toxin. J Biosci Bioeng. 2002;94:93–98.
6. Rao YUB, Mahadevan MS, Michaels LS. Evaluation of microporous tangential-flow filtration in the production of diptheria
and pertussis vaccines. Pharm Technol. 1992;16:102-110.
7. Stainer DW, Scholte MJ. A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol.
1970;63:211–220.
|
